PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of “Moderate Buy” by Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $69.00.

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of PTC Therapeutics in a report on Wednesday, September 3rd. Royal Bank Of Canada reissued an “outperform” rating and set a $63.00 price objective (up previously from $60.00) on shares of PTC Therapeutics in a research report on Friday, August 8th. Wells Fargo & Company decreased their target price on PTC Therapeutics from $79.00 to $73.00 and set an “overweight” rating on the stock in a report on Wednesday, August 20th. Barclays boosted their price target on PTC Therapeutics from $42.00 to $46.00 and gave the company an “equal weight” rating in a report on Tuesday, July 29th. Finally, Truist Financial lifted their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 29th.

PTC Therapeutics Stock Up 2.8%

Shares of PTCT stock opened at $60.65 on Tuesday. The company has a 50 day moving average price of $52.86 and a 200-day moving average price of $50.01. PTC Therapeutics has a 52 week low of $34.57 and a 52 week high of $63.19. The firm has a market capitalization of $4.82 billion, a PE ratio of 8.70 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.24. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The company had revenue of $178.88 million for the quarter, compared to the consensus estimate of $173.01 million. During the same quarter in the prior year, the firm earned ($1.29) earnings per share. The firm’s revenue for the quarter was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. Analysts anticipate that PTC Therapeutics will post -4.52 earnings per share for the current year.

Insider Transactions at PTC Therapeutics

In other news, Director David P. Southwell sold 12,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $58.34, for a total transaction of $700,080.00. Following the sale, the director directly owned 16,850 shares in the company, valued at $983,029. This trade represents a 41.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Pauwels sold 39,850 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $56.92, for a total transaction of $2,268,262.00. Following the completion of the transaction, the insider directly owned 72,912 shares of the company’s stock, valued at $4,150,151.04. This represents a 35.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 131,393 shares of company stock valued at $7,640,615. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTCT. Ameritas Investment Partners Inc. raised its position in shares of PTC Therapeutics by 3.0% during the second quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 231 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 295 shares in the last quarter. Xponance Inc. boosted its holdings in shares of PTC Therapeutics by 5.2% during the 1st quarter. Xponance Inc. now owns 6,372 shares of the biopharmaceutical company’s stock valued at $325,000 after purchasing an additional 314 shares during the last quarter. Diversified Trust Co grew its position in shares of PTC Therapeutics by 2.0% during the first quarter. Diversified Trust Co now owns 17,147 shares of the biopharmaceutical company’s stock valued at $874,000 after purchasing an additional 329 shares in the last quarter. Finally, GF Fund Management CO. LTD. increased its holdings in shares of PTC Therapeutics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,974 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 355 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.